| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FOXJ1 |
| Uniprot No | Q92949 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-421aa |
| 氨基酸序列 | MAESWLRLSG AGPAEEAGPE GGLEEPDALD DSLTSLQWLQ EFSILNAKAP ALPPGGTDPH GYHQVPGSAA PGSPLAADPA CLGQPHTPGK PTSSCTSRSA PPGLQAPPPD DVDYATNPHV KPPYSYATLI CMAMQASKAT KITLSAIYKW ITDNFCYFRH ADPTWQNSIR HNLSLNKCFI KVPREKDEPG KGGFWRIDPQ YAERLLSGAF KKRRLPPVHI HPAFARQAAQ EPSAVPRAGP LTVNTEAQQL LREFEEATGE AGWGAGEGRL GHKRKQPLPK RVAKVPRPPS TLLPTPEEQG ELEPLKGNFD WEAIFDAGTL GGELGALEAL ELSPPLSPAS HVDVDLTIHG RHIDCPATWG PSVEQAADSL DFDETFLATS FLQHPWDESG SGCLPPEPLF EAGDATLASD LQDWASVGAF L |
| 预测分子量 | 45,2 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组蛋白在免疫检测及疫苗开发领域的3篇参考文献概要：
1. **《重组蛋白疫苗的免疫原性研究》- 作者：李明等**
摘要：研究通过基因工程技术表达SARS-CoV-2刺突蛋白受体结合域(RBD)，并在动物模型中验证其免疫原性。结果显示，重组蛋白疫苗能诱导高水平中和抗体，且安全性良好，为后续临床试验奠定基础。
2. **《基于重组抗原的新型诊断试剂开发》- 作者：王芳团队**
摘要：利用重组表达的结核分枝杆菌抗原ESAT-6和CFP-10.开发出高灵敏度免疫层析检测试纸。临床样本测试显示，该试剂特异性达95%，显著优于传统PPD检测方法，适用于快速筛查结核感染。
3. **《禽流感病毒重组血凝素蛋白的免疫保护效应》- 作者：张伟等**
摘要：通过杆状病毒表达系统制备H5N1禽流感病毒HA蛋白，动物实验表明，重组蛋白疫苗可有效激发Th1/Th2混合免疫应答，攻毒实验显示免疫组存活率达90%，证实其具有潜在应用价值。
注：以上文献为模拟摘要，实际研究请通过学术数据库检索。建议使用"重组蛋白疫苗"、"免疫诊断试剂"等规范术语结合具体靶点(如COVID-19、HPV等)进行精准检索。
**Background of Recombinant Protein COVID-19 Vaccines (Conditionally Approved Clinical Trials)**
Recombinant protein vaccines represent a well-established approach in vaccine development, leveraging genetic engineering to produce antigenic proteins without using live pathogens. For COVID-19. these vaccines typically focus on the spike (S) protein of SARS-CoV-2. which facilitates viral entry into human cells. The S protein is encoded into expression systems (e.g., insect or mammalian cells, yeast) to generate large quantities of the antigen, which is then purified and combined with adjuvants to enhance immune responses.
The conditional approval of clinical trials for such vaccines often follows promising preclinical data, demonstrating safety and immunogenicity. During the pandemic, regulatory agencies like China’s NMPA and the WHO endorsed accelerated pathways, allowing phased clinical trials to proceed concurrently with scaled manufacturing. For instance, China’s ZF2001 (developed by Anhui Zhifei Longcom) utilized a dimeric spike protein with an aluminum-based adjuvant. Early-phase trials showed robust neutralizing antibody production and tolerable side effects, prompting conditional approval for Phase III trials even as data collection continued.
This strategy balanced urgency and safety, addressing global demand while maintaining scientific rigor. Recombinant protein vaccines offer advantages over mRNA or viral vector platforms, such as stability under refrigeration and fewer cold-chain requirements, making them viable for resource-limited regions. However, challenges include optimizing adjuvants for long-lasting immunity and adapting to emerging variants.
Overall, conditionally approved trials for recombinant protein COVID-19 vaccines exemplify a coordinated effort to merge rapid development with regulatory oversight, aiming to deliver safe, effective, and accessible solutions during a public health crisis. Their development underscores the versatility of protein-based platforms in pandemic preparedness.
(Word count: 398)
×
